Preparation of 10-hydroxycamptothecin proliposomes by the supercritical CO2 anti-solvent process

Chemical Engineering Journal

Volumn 243, Issue , 2014, Pages 289-296

  Liu, Guijin ^a   Wang, Wei ^a   Wang, Hongdi ^a   Jiang, Yanbin ^a  

^a SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

10 Hydroxycamptothecin; Orthogonal experimental design; Proliposomes; Release kinetics; Supercritical anti solvent

Indexed keywords

10 HYDROXYCAMPTOTHECIN (HCPT); ORTHOGONAL EXPERIMENTAL DESIGN; PROLIPOSOMES; RELEASE KINETICS; SUPERCRITICAL ANTISOLVENTS;

CARBON DIOXIDE; CHOLESTEROL; CRYSTALLINE MATERIALS; ENCAPSULATION; LECITHIN; OPTIMIZATION; PARTICLE SIZE ANALYSIS; SOLVENTS; STATISTICS;

DRUG PRODUCTS;

EID: 84893385508     PISSN: 13858947     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cej.2014.01.023     Document Type: Article

References (37)

1. Wall M.E., Wani M.C., Cook C.E., Palmer K.H., McPhail A.T., Sim G.A. Plant anti-tumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 1966, 88:3888-3890.
2. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase. I. J. Biol. Chem. 1985, 260:14873-14878.
3. Han R. Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells 1994, 12:53-63.
4. Ping Y.H., Lee H.C., Lee J.Y., Wu P.H., Ho L.K., Chi C.W., Lu M.F., Wang J.J. Anticancer effects of low-dose 10-hydroxycamptothecin in human colon cancer. Oncol. Rep. 2006, 15:1273-1279.
5. Yang J., Ni B., Liu J., Zhu L., Zhou W. Application of liposome-encapsulated hydroxycamptothecin in the prevention of epidural scar formation in New Zealand white rabbits. Spine J. 2011, 11:218-223.
6. Rivory L.P., Robert J. Molecular, cellular, and clinical aspects of the pharmacology of 20(S) camptothecin and its derivatives. Pharmacol. Ther. 1995, 68:269-296.
7. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res. 1994, 54:1431-1439.
8. O'Leary J., Muggia F.M. Camptothecins: a review of their development and schedules of administration. Eur. J. Cancer 1998, 34:1500-1508.
9. Venditto V.J., Simanek E.E. Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol. Pharm. 2010, 7:307-349.
10. Zhang C., Ding Y., Yu L.L., Ping Q. Polymeric micelle systems of hydroxycamptothecin based on amphiphilic N-alkyl-N-trimethyl chitosan derivatives. Colloid Surface B 2007, 55:192-199.
11. Zhao Y.X., Gao J.Q., Sun X.Y., Chen H.L., Wu L.M., Liang W.Q. Enhanced nuclear delivery and cytotoxic activity of hydroxycamptothecin using O/W emulsions. J. Pharm. Sci. 2007, 10:61-70.
12. Pu X.H., Sun J., Wang Y., Wang Y.J., Liu X.H., Zhang P., Tang X., Pan W.S., Han J.H., He Z.G. Development of a chemically stable 10-hydroxycamptothecin nanosuspension. Int. J. Pharm. 2009, 379:167-173.
13. Hong M.H., Zhu S.J., Jiang Y.Y., Tang G.T., Pei Y.Y. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferring. J. Control. Release 2009, 133:96-102.
14. Lu B., Zhang Z.Q. Novel colon-specific microspheres with highly dispersed hydroxycamptothecin cores: their preparation, release behavior and therapeutic efficiency against colonic cancer. J. Pharm. Sci. 2006, 95:2619-2630.
15. Lee Y., Cui F.D., Cun D.M., Tao A.J., Shi K., Lin W.H. Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles. Int. J. Pharm. 2007, 340:163-172.
16. Pal A., Khan S., Wang Y.F., Kamath N., Sarkar A.K., Ahmad A., Sheikh S., Ali S., Carbonaro D., Zhang A., Ahmad I. Preclinical safety, pharmacokinetics and anti-tumor efficacy profile of liposome-entrapped SN-38 formulation. Anti-cancer Res. 2005, 25:331-341.
17. Khan S., Ahmad A., Guo W., Wang Y.F., Abu-Qare A., Ahmad I. A simple and sensitive LC/MS/MS assay for 7-ethyl-10-hydroxycamptothecin (SN-38) in mouse plasma and tissues: application to pharmacokinetic study of liposome entrapped SN-38 (LE-SN38). J. Pharm. Biomed. Anal. 2005, 37:135-142.
18. Xuan T., Zhang J.A., Ahmad I. HPLC method for determination of SN-38 content and SN-38 entrapment efficiency in a novel liposome-based formulation, LE-SN38. J. Pharm. Biomed. Anal. 2006, 41:582-588.
19. Zhao Y.X., Gao J.Q., Qiao H.L., Chen H.L., Liang W.Q. Development and validation of a sensitive reversed-phase HPLC method to determine intracellular accumulation of hydroxycamptothecin. J. Pharm. Biomed. Anal. 2006, 41:1007-1010.
20. Shi K., Tian Y., Jiang Y., Wang L., Cui F. Modified hydrolysis kinetics of the active lactone moiety of 10-hydroxycamptothecin by liposomal encapsulation. Pharm. Dev. Technol. 2010, 15:644-652.
21. Lesoin L., Crampon C., Boutin O., Badens E. Preparation of liposomes using the supercritical anti-solvent (SAS) process and comparison with a conventional method. J. Supercrit. Fluids 2011, 57:162-174.
22. Payne N.I., Timmis P., Ambrose C.V., Warel M.D., Ridgway F. Proliposomes: a novel solution to an old problem. J. Pharm Sci. 1986, 75:325-329.
23. Shaji J., Bhatia V. Proliposomes: a brief overview of novel delivery system. Int. J. Pharm. Bio. Sci. 2013, 4:150-160.
24. Bayat Y., Pourmortazavi S.M., Ahadi H., Iravani H. Taguchi robust design to optimize supercritical carbon dioxide anti-solvent process for preparation of 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazaisowurtzitane nanoparticles. Chem. Eng. J. 2013, 230:432-438.
25. Chen Y.M., Tang M., Chen Y.P. Recrystallization and micronization of sulfathiazole by applying the supercritical anti-solvent technology. Chem. Eng. J. 2010, 165:358-364.
26. Cocero M.J., Martín Á., Mattea F., Varona S. Encapsulation and co-precipitation processes with supercritical fluids: fundamentals and applications. J. Supercrit. Fluids 2009, 47:546-555.
27. 2 anti-solvent process using dichloromethane/ethanol co-solvent. J. Supercrit. Fluids 2013, 74:137-144.
28. Li W.F., Liu G.J., Li L.X., Wu J., Lv Y.X., Jiang Y.B. Effect of process parameters on Co-precipitation of paclitaxel and poly(l-lactic acid) by supercritical antisolvent process. Chin. J. Chem. Eng. 2012, 20:803-813.
29. Jiang Y.B., Sun W.L., Wang W. Recrystallization and micronization of 10-hydroxycamptothecin by supercritical anti-solvent process. Ind. Eng. Chem. Res. 2012, 51:2596-2602.
30. Liu G.J., Wang H.D., Jiang Y.B. Recrystallization and micronization of camptothecin by supercritical antisolvent process: influence of solvents. Ind. Eng. Chem. Res. 2013, 52:15049-15056.
31. Zhang L., Yang M., Wang Q., Li Y., Guo R., Jiang X., Yang C., Liu B. 10-Hydroxycamptothecin loaded nanoparticles: preparation and antitumor activity in mice. J. Control. Release 2007, 119:153-162.
32. 2. Langmuir 2008, 24:7432-7441.
33. Wang J.L., Wang R., Li L.B. Preparation and properties of hydroxycamptothecin-loaded nanoparticles made of amphiphilic copolymer and normal polymer. J. Colloid Interface Sci. 2009, 336:808-813.
34. Hassan E.E., Parish R.C., Gallo J.M. Optimized formulation of magnetic chitosan microspheres containing the anticancer agent, oxantrazole. Pharm. Res. 1992, 9:390-397.
35. Zhu X., Zhang C., Wu X., Tang X., Ping Q. Preparation, physical properties, and stability of gambogic acid-loaded micelles based on chitosan derivatives. Drug Dev. Ind. Pharm. 2008, 34:2-9.
36. Costa P., Lobo J.M.S. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 2001, 13:123-133.
37. Korsmeyer R.W., Gurny R., Doelker E.M., Buri P., Peppas N.A. Mechanism of solute release from porous hydrophilic polymers. Int. J. Pharm. 1983, 15:25-35.